Yahoo Finance Today’s Research Reports on Oncolytics Biotech, CardioComm Solutions, BELLUS Health and Aphria
NEW YORK, NY / ACCESSWIRE / May 4, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI has Initiated Coverage Today on:
Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO
CardioComm Solutions, Inc.
https://rdinvesting.com/news/?ticker=EKG.V
BELLUS Health Inc.
https://rdinvesting.com/news/?ticker=BLU.TO
Aphria Inc.
https://rdinvesting.com/news/?ticker=APH.TO
Oncolytics Biotech's stock moved 3.28% higher Thursday, to close the day at $0.63. The stock recorded a trading volume of 75,776 shares, which was below its three months average volume of 168,373 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 0.42 - 1.12. The share price has gained 50.00% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.69 is below its 200-day moving average of $0.71. Shares of Oncolytics Biotech have fallen approximately 11.27 percent year-to-date.
Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO
On Thursday, shares of CardioComm Solutions recorded a trading volume of 10,000 shares, which was below the three months average volume of 116,960 shares. The stock ended the day flat at 0.04. The stock is currently trading 65.38% below its 52-week high with a 52-week trading range of 0.05 - 0.13. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $0.05 is below its 200-day moving average of $0.052.
Access RDI's CardioComm Solutions, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=EKG.V
BELLUS Health's stock jumped 6.12% Thursday, to close the day at $0.52. The stock recorded a trading volume of 1,264,797 shares, which was above its three months average volume of 254,070 shares. In the last year, BELLUS Health's shares have traded in a range of 0.28 - 0.60. The share price has gained 85.71% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.49 is greater than its 200-day moving average of $0.43.
Shares of BELLUS Health have gained approximately 40.54 percent year-to-date.
Access RDI's BELLUS Health Inc. Research Report at:
https://rdinvesting.com/news/?ticker=BLU.TO
On Thursday, shares of Aphria recorded a trading volume of 1,722,782 shares, which was below the three months average volume of 4,381,008 shares. The stock ended the day 0.81% higher at 9.92. The share price has gained 118.02% from its 52-week low with a 52-week trading range of 4.55 - 24.75. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $11.45 is below its 200-day moving average of $13.20. Shares of the company are trading at a Price to Earnings ratio of 47.46. Shares of Aphria have fallen approximately 46.95 percent year-to-date.
Access RDI's Aphria Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APH.TO
Our Actionable Research on Oncolytics Biotech Inc. (TSX:ONC.TO), CardioComm Solutions, Inc. (TSXV:EKG.V), BELLUS Health Inc. (TSX:BLU.TO) and Aphria Inc. (TSX:APH.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
